Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Healthcare Biotechnology
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Arbutus Biopharma Corp
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Stockhunton Aug 28, 2014 9:07am
171 Views
Post# 22885403

RE:tekmira-surges-on-takeover-rumors

RE:tekmira-surges-on-takeover-rumors

Merger mania in healthcare sector keeps dealers on toes during peak holiday weeks with Tekmira now high on takeover tonic

Rumours suggest two of the interested parties could be the UK’s Shire (22p off at 4894p) and GlaxoSmithKline (15.5p dearer at 1463p. The mega premium paid for InterMune puts a valuation of $40 plus a-share on Tekmira.
Read more: https://www.thisismoney.co.uk/money/markets/article-2735978/MARKET-REPORT-Tekmira-high-takeover-tonic-healthcare-sector.html#ixzz3BgwxbnJm
Follow us: @MailOnline on Twitter | DailyMail on Facebook

https://www.thisismoney.co.uk/money/markets/article-2735978/MARKET-REPORT-Tekmira-high-takeover-tonic-healthcare-sector.html
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities